Corbus Pharma tumbles on stock offering plans

Corbus Pharmaceuticals Holdings

30/10/2025 21:15

** Shares of Corbus Pharmaceuticals CRBP.O down 16.3% in extended trading to $13.76 after planned equity raise news

    ** Norwood, Massachusetts-based oncology and obesity co announces offering of stock and pre-funded warrants without disclosing targeted deal size

** It intends to use net offering proceeds to fund clinical development of its pipeline and for working capital and other purposes

** Jefferies and Piper Sandler are joint bookrunners

** With ~12.26 mln shares outstanding, co has about $200 mln market cap

** CRBP shares on Thurs closed down 2.5% at $16.44. Stock up 77% over the past three months, putting it up 39% YTD

** Earlier this month, co shared early-stage data of CRB-701, its experimental therapy for head and neck cancer that has returned or spread after earlier treatments, at the annual European Society for Medical Oncology

** All 10 analysts covering CRBP are bullish and their median PT is $40, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))